LCAT and chronic kidney disease: Calabresi et al. reported that acquired plasma lecithin cholesterol acyltransferase (LCAT) deficiency was a major cause of low plasma HDL levels in patients with CKD, making it an attractive therapeutic target to reverse dyslipidaemia and reduce potential cardiovascular events (27).